2026-08-12 | Immunocyte phenotypes underlying the causal autoimmune features in narcolepsy type 1.
Narcolepsy is a neurological sleep disorder associated with immune response. However, the autoimmune basis for narcolepsy remains unclear. This study aimed to evaluate the causal relationship between immune cells and narcolepsy type 1 (NT1). We used a two-sample Mendelian randomization (MR) method to investigate the associations between 731 immune cell traits and NT1 based on a genome-wide association study (GWAS) database from the FinnGen consortium. The inverse-variance weighted (IVW) method was used as the primary method, followed by sensitivity analyses, including the MR-Egger intercept test, Cochran's Q test, and MR pleiotropy residual sum and outlier (MR-PRESSO). Additional mediation analysis was conducted to investigate the mediating effect of 91 cytokines on immune cells to facilitate the immune processes in NT1. Immune cell traits showed significant causal associations with NT1. Risk-associated traits mainly involved human leukocyte antigen-DR (HLA-DR)-related monocyte phenotypes, T-cell-related traits, natural killer (NK) cell-related traits, and natural killer T (NKT) cell-related traits, whereas protective traits mainly involved CD4+ T-cell-related, plasmacytoid dendritic cell-related, monocyte-related, and B-cell-related phenotypes. Overall, ten immune cell traits were associated with an increased risk of narcolepsy, whereas five were associated with a reduced risk. Mediation analysis further indicated that interleukin-6 (IL-6) mediates the immune-inflammatory pathway linking monocyte-related traits to NT1. These findings remained consistent in all sensitivity analyses. Our study identified immunophenotypes that are related to the development of NT1, providing insight into the autoimmune pathogenesis of NT1 and subsequent immunotherapy.
Open article ↗
2026-07-31 | Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders.
Sleep is emerging as a key health topic in modern society. The prevalence of and focus on sleep-wake disorders is increasing, which has led to a large interest from the pharmaceutical industry to develop new treatments targeting sleep biology (that is, drugs that have the potential to mimic normal sleep-wake physiology). The orexin (also known as hypocretin) system is one of the key targets and regulators of sleep and wakefulness. In this Review, we will discuss the mechanisms by which loss of orexin signalling is involved in narcolepsy type 1 and whether loss and/or disruption of orexin signalling might have a role in other sleep disorders such as narcolepsy type 2, idiopathic hypersomnia and obstructive sleep apnoea. We will also describe current and emerging therapies for sleep disorders involving orexin, such as orexin receptor antagonists for insomnia and orexin receptor agonists for narcolepsy.
Open article ↗
2026-07-23 | Optimizing patient outcomes and empowering the patient-clinician partnership.
The treatment landscape for narcolepsy is rapidly evolving with the introduction of new therapies featuring unique mechanisms of action and innovative formulations of established treatments. The recent approval of a once-nightly sodium oxybate formulation (SO-ER) has expanded the spectrum of oxybate therapies to 3, including the traditional immediate-release formulation (OXB) and a low-sodium version containing calcium, magnesium, potassium, and sodium oxybates (LXB). While the availability of diverse options allows clinicians to tailor oxybate-based treatments, it also raises challenges in selecting and fine-tuning these therapies. Involving patients in the decision-making process through shared decision-making (SDM) platforms can be an effective approach to optimizing oxybate therapy. This review article aims to provide clinicians with a comprehensive overview of the unique characteristics of available oxybate formulations and potential strategies for delivering empathetic care that incorporates SDM into the selection and optimization of oxybate-based treatment regimens.
Open article ↗
2026-07-20 | Development of Narcolepsy Type 1 Following COVID-19 Infection in a Patient Previously Diagnosed With Idiopathic Hypersomnia: A Case Report
Narcolepsy type 1 is a rare sleep disorder characterized by excessive daytime sleepiness (EDS) and cataplexy, thought to result from the immune-mediated destruction of hypocretin-producing neurons in genetically susceptible individuals. Viral infections have been implicated as potential environmental triggers. We present the case of a 17-year-old female National Collegiate Athletic Association (NCAA) Division I student-athlete with a prior diagnosis of idiopathic hypersomnia who developed new-onset cataplexy following COVID-19 infection. Initial polysomnography and multiple sleep latency testing demonstrated severe hypersomnolence without sleep-onset rapid eye movement periods. Several months later, she developed emotionally triggered episodes of muscle weakness consistent with cataplexy. Repeat multiple sleep latency testing demonstrated only one sleep-onset rapid eye movement period; however, given the development of typical cataplexy and the overall clinical presentation, a clinical diagnosis of narcolepsy type 1 was made. Cerebrospinal fluid hypocretin testing was not performed. Symptoms were refractory to multiple stimulant and antidepressant regimens but responded well to sodium oxybate in combination with solriamfetol, resulting in the resolution of EDS and cataplexy. This case highlights a possible temporal association between COVID-19 infection and the subsequent development of narcolepsy type 1 and underscores the importance of clinical judgment when objective diagnostic testing is inconclusive.
Open article ↗
2026-07-15 | Oxytocin promotes socially triggered cataplexy.
People with narcolepsy have intrusive episodes of muscle weakness known as cataplexy, which are usually triggered by strong, positive emotions. As cataplexy occurs almost exclusively during social interactions, we examined whether it is promoted by the prosocial neuropeptide oxytocin. In a mouse model of narcolepsy, social reunification triggered cataplexy, and an oxytocin antagonist blocked socially induced cataplexy episodes. Oxytocin tone and the activity of oxytocin receptor-expressing neurons in the central amygdala both increased just before cataplexy triggered by social stimuli. Chemo- and optogenetic manipulations demonstrated that oxytocin-responsive neurons in the central amygdala drive cataplexy by inhibiting brainstem neurons that suppress muscle atonia. In addition, chocolate, a rewarding stimulus associated with strong, positive emotions, also engages this oxytocin-amygdala pathway and triggers cataplexy in narcoleptic mice. Together, these findings show that oxytocin acts through the amygdala to promote cataplexy triggered by social and other rewarding stimuli, offering new opportunities for treating cataplexy.
Open article ↗
